TY - JOUR
T1 - Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana
AU - Boateng, Anthony T.
AU - Aboagye, James O.
AU - Lamptey, Helena
AU - Abana, Christopher Z.Y.
AU - Abaidoo-Myles, Araba
AU - Quansah, Darius N.K.
AU - Agyemang, Seth
AU - Awuku-Larbi, Yaw
AU - Ansa, Gloria
AU - Oliver-Commey, Joseph
AU - Ganu, Vincent
AU - Kyei, George B.
AU - Puplampu, Peter
AU - Bonney, Evelyn Y.
N1 - Publisher Copyright:
Copyright © 2025 Boateng, Aboagye, Lamptey, Abana, Abaidoo-Myles, Quansah, Agyemang, Awuku-Larbi, Ansa, Oliver-Commey, Ganu, Kyei, Puplampu and Bonney.
PY - 2025
Y1 - 2025
N2 - Introduction: Regular viral load (VL) testing for people living with HIV (PLWH) is key to attaining the Joint United Nations Program on HIV/AIDS (UNAIDS) Fast-Track 95–95-95 target to end the HIV epidemic by 2030. However, VL testing remains sporadic in routine HIV care in the majority of resource-limited settings, including Ghana, except when provided through research initiatives. In this study, we measured VL among PLWH in Ghana at regular intervals and investigated factors affecting viral suppression (VS) and rebound. Methods: We analyzed data from a hospital-based cohort enrolled in our HIV cure research. Participants were recruited from three hospitals in the Greater Accra region of Ghana. Demographic characteristics were obtained from participants’ folders, while CD4+ T cell counts and VLs were measured from blood samples collected at baseline, 6 months, and 18 months. Results: The study participants were predominantly women (68%) with a median age of 45 years (IQR: 21–76 years). A total of 52% of participants had been on antiretroviral therapy (ART) for more than 6 years, and 74% were following dolutegravir-based regimens. At baseline, 74% of participants had a VL of <50 copies/mL, which increased to 88% at 18 months, with 80% having a CD4+ T cell count of >350 cells/μl. Age group [<40 vs. > 40 years] (OR 2.35, 95% CI; 1.21–4.58, p = 0.012), CD4+ T cell count [>350 vs. < 350 cells/μl] (OR 4.35, 95% CI; 2.32–8.18, p < 0.001), and ART regimen [NVP based vs. DTG based] (OR 7.00, 95% CI; 1.15–42.57, p = 0.034) were associated with VS of <50 copies/mL. The overall viral rebound rate was estimated at 13.61 per 1,000 person-months (95% CI 10.52–17.74), with decreasing rates over time. Lower educational levels (up to Junior High School) were significantly associated with viral rebound (p = 0.011). Conclusion: A key feature of our study was measuring VL at three time points over 2 years, which may explain the high VS levels observed. Viral rebound was linked to low education levels, highlighting the need for targeted education for PLWH with junior high school (JHS) education or less. Regular VL monitoring and the implementation of measures to prevent viral rebound, particularly among PLWH with lower education levels, will help Ghana move closer to attaining the third “95” of the UNAIDS 95–95-95 target by 2030.
AB - Introduction: Regular viral load (VL) testing for people living with HIV (PLWH) is key to attaining the Joint United Nations Program on HIV/AIDS (UNAIDS) Fast-Track 95–95-95 target to end the HIV epidemic by 2030. However, VL testing remains sporadic in routine HIV care in the majority of resource-limited settings, including Ghana, except when provided through research initiatives. In this study, we measured VL among PLWH in Ghana at regular intervals and investigated factors affecting viral suppression (VS) and rebound. Methods: We analyzed data from a hospital-based cohort enrolled in our HIV cure research. Participants were recruited from three hospitals in the Greater Accra region of Ghana. Demographic characteristics were obtained from participants’ folders, while CD4+ T cell counts and VLs were measured from blood samples collected at baseline, 6 months, and 18 months. Results: The study participants were predominantly women (68%) with a median age of 45 years (IQR: 21–76 years). A total of 52% of participants had been on antiretroviral therapy (ART) for more than 6 years, and 74% were following dolutegravir-based regimens. At baseline, 74% of participants had a VL of <50 copies/mL, which increased to 88% at 18 months, with 80% having a CD4+ T cell count of >350 cells/μl. Age group [<40 vs. > 40 years] (OR 2.35, 95% CI; 1.21–4.58, p = 0.012), CD4+ T cell count [>350 vs. < 350 cells/μl] (OR 4.35, 95% CI; 2.32–8.18, p < 0.001), and ART regimen [NVP based vs. DTG based] (OR 7.00, 95% CI; 1.15–42.57, p = 0.034) were associated with VS of <50 copies/mL. The overall viral rebound rate was estimated at 13.61 per 1,000 person-months (95% CI 10.52–17.74), with decreasing rates over time. Lower educational levels (up to Junior High School) were significantly associated with viral rebound (p = 0.011). Conclusion: A key feature of our study was measuring VL at three time points over 2 years, which may explain the high VS levels observed. Viral rebound was linked to low education levels, highlighting the need for targeted education for PLWH with junior high school (JHS) education or less. Regular VL monitoring and the implementation of measures to prevent viral rebound, particularly among PLWH with lower education levels, will help Ghana move closer to attaining the third “95” of the UNAIDS 95–95-95 target by 2030.
KW - ART
KW - HIV
KW - viral load
KW - viral rebound
KW - viral suppression
UR - http://www.scopus.com/inward/record.url?scp=105001649960&partnerID=8YFLogxK
U2 - 10.3389/fpubh.2025.1508793
DO - 10.3389/fpubh.2025.1508793
M3 - Article
AN - SCOPUS:105001649960
SN - 2296-2565
VL - 13
JO - Frontiers in Public Health
JF - Frontiers in Public Health
M1 - 1508793
ER -